CARsgen Presents CAR-Claudin18.2-T Data at 2018 CAR-TCR Summit

Corporate Breaking News

Home : CARsgen Presents CAR-Claudin18.2-T Data at 2018 CAR-TCR Summit

Sep 08 2018	CARsgen Presents CAR-Claudin18.2-T Data at 2018 CAR-TCR Summit
BOSTON, Sept. 8, 2018 /PRNewswire/ -- CARsgen Therapeutics, a clinical-stage company committed to developing Chimeric Antigen Receptor T cell therapies for cancer, presented its preliminary clinical data of a first-in-class CAR-Claudin18.2 T cell trial for treatment of pancreatic and...


Source:https://www.prnewswire.com:443/news-releases/carsgen-presents-car-claudin18-2-t-data-at-2018-car-tcr-summit-300709170.html

Related News
» After School Program Helping Hundreds of Students » TESLA BRANDS SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Tesla, Inc. - TSLA